Celebrating Eczema Awareness Month 2025 with Dermatology Times

Today is the last day of Eczema Awareness Month, recognized annually every October. Atopic dermatitis affects approximately 10 to 30% of children and 2 to 10% of adults in the US.¹ Its burden extends far beyond skin symptoms, greatly impairing quality of life of patients of all ages.

Dermatology Times brings together the latest in eczema news from novel treatment approvals to patient-advocacy research. Below, you’ll find the top news insights and expert-led interviews from the month that are shaping the future of diagnosis, research, and treatment for patients with AD.

Q&A: Danielle Jonas on Eczema Awareness Month, Finding Clinician Support, and Why Laundry Impacts Skin Health

Patient advocate Danielle Jonas shares her journey with atopic dermatitis, emphasizing the importance of trusted products and clinician support during Eczema Awareness Month.

FDA Expands Roflumilast Access to Children as Young as Age 2

The approval represents the sixth FDA authorization for roflumilast since 2022.

Sitryx Advances Novel Oral Therapy SYX-5219 for Atopic Dermatitis with FDA IND Clearance

Sitryx Therapeutics advances SYX-5219 for moderate to severe AD, aiming for a first-in-class oral treatment with potential for lasting disease remission.

APG777 May Ease Burden on Patients With AD

The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.

Eichenfield Highlights Clinical Value of Roflumilast Cream for Pediatric AD

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

Dermatology Steps Forward in Onco-Skin Management

Radiation dermatitis significantly affects breast cancer patients, impacting quality of life and treatment. Discover effective prevention and management strategies.

Case-Based Strategies for Optimizing AD Care

During a Case-Based Roundtable event, Naiem Issa, MD, PhD, guided colleagues through 3 complex atopic dermatitis cases, highlighting how modern topicals can deliver rapid and durable control across age groups.

Investigating a New 4% Glycyrrhetinic Acid Treatment Approach for SSD

A novel 4% glycyrrhetinic acid scalp gel shows rapid relief for mild to moderate seborrheic dermatitis, enhancing treatment options with herbal ingredients.

Remote Assessment of AD Via Mobile App Shows High Agreement with Clinic Visits

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.

Derm Dispatch: Lessons from the Eczema Community

The episode underscores the clinical value of listening to patient advocates who bring firsthand understanding of disease impact.

Nemolizumab Maintains Long-Term Efficacy in AD

In the ARCADIA LTE, nemolizumab maintained significant and progressive improvements in skin and itch outcomes for up to 104 weeks.

Unlocking the Potential of the OX40 Pathway in Atopic Dermatitis Treatment

Experts discuss the OX40 pathway's potential to transform atopic dermatitis treatment, addressing unmet needs and promising new therapies for better patient outcomes.

Dupilumab Shows Durable 2-Year Efficacy in Pediatric AD

The findings reinforce dupilumab as a safe, long-term cornerstone therapy for pediatric AD, with emerging flexibility in treatment scheduling.

Exploring Novel Topical Treatments for Atopic Dermatitis: Clinical Insights from Patient Cases

At a recent Case-Based Roundtable event, John Browning, MD, led a discussion on evolving strategies for AD management

Top Advancements From 2025 on AD, HS, PsO, CSU, and More

James Del Rosso, DO; April Armstrong, MD, MPH; Mark Nestor, MD, PhD; Mark Lebwohl, MD; Linda Stein Gold, MD; and Darrell Rigel, MD, MS, presented some of the biggest updates in dermatology to close out the year.

Exploring the OX40 Ligand Pathway and Chronic Itch

At Fall Clinical 2025, Shawn Kwatra, MD, presented insights on managing various cases of chronic itch, as well as understanding the OX40 ligand pathway as the “prequel to inflammation.”

Expanding Role of IL-13–Targeted Biologics for Atopic Dermatitis

At Fall Clinical 2025, Mona Shahriari, MD, presented highlights on the role of IL-13 inhibitors, such as dupilumab, tralokinumab, and lebrikizumab, in managing atopic dermatitis across severities.

Ruxolitinib Cream Shows Strong AD Efficacy and Rapid Itch Relief in TRuE-AD4 Trial

Incyte reveals promising TRuE-AD4 trial results for ruxolitinib cream, showcasing its effectiveness and safety for adults with moderate atopic dermatitis.

Roflumilast Cream 0.05% Now Commercially Available for Pediatric Atopic Dermatitis

Arcutis has expanded roflumilast cream in the US, a steroid-free treatment for mild to moderate AD in young children.

Reference

1. Eczema (Atopic Dermatitis). National Institute of Allergy and Infectious Diseases. https://www.niaid.nih.gov/diseases-conditions/eczema-atopic-dermatitis